Novira raises $11M in stock sale, focused on hep B, HIV
Novira试图在股票市场募集1100万美金专注于HBV和HIV药物研发
Philadelphia Business Journal by John George, Senior Reporter
Date: Thursday, August 23, 2012, 12:59pm EDT
Novira Therapeutics raised $11 million in a private stock sale, according to documents filed with the Securities and Exchange Commission.
The Radnor, Pa., biopharmaceutical company is seeking to raise a total of $26.5 million, according to the filing.
Novira is an antiviral drug discovery company founded in 2009. It is focusing on the discovery and development of novel treatments for HBV, the hepatitis B virus, and HIV, which causes AIDS.
The company’s proprietary technology is being used to create antiviral drugs that bind to and disrupt the function of virus proteins called “capsids,” which are associated with HBV and HIV.
Novira expects to begin human safety and efficacy studies of its new drug candidate targeting HBV next year.
Osvaldo (Lalo) Flores, the president and chief scientific officer of Novira Therapeutics in Radnor, Pennsylvania, told MedCity News in a phone interview that the biotechnology company’s capsid-targeting antivirals entering preclinical development are potentially more effective than what is currently available.
奥斯瓦尔多·弗洛雷斯（拉罗）总裁兼首席科学官，宾夕法尼亚州拉德诺的Novira治疗，在接受电话采访时告诉MedCity新闻，衣壳蛋白靶向的生物技术公司的抗病毒药物进入临床前开发比目前可能更有效。
“We believe our drug either alone or in combination with others has the potential to lead to better cure rates,” Flores said. “It will lead to better efficacy because it is expected to lead to faster and greater reduction of cccDNA compared to currently available drugs, which will improve outcomes,” said Flores, adding that the company expects to enter clinical trials with its lead hepatitis B program in early 2014.”
“我们相信，我们单独或与其他药物有可能导致更佳的治愈率，”弗洛雷斯说。 “，这将导致更好的疗效，因为它预计将导致更快，更大的降低cccDNA水平相比，目前可用的药物，这将改善预后，”弗洛雷斯说，补充说，该公司预计将进入临床试验阶段，其领先的B型肝炎程序在2014年初开始。“ 作者: 咬牙硬挺 时间: 2012-8-25 21:46
